ClinicalTrials.gg
CompletedNCT02860546Updated Sep 3, 2024Results posted

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

A Phase 2 interventional study of TAS-102 and nivolumab in Refractory Metastatic Colorectal Cancer, sponsored by Taiho Oncology, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.

Enrollment
31st of 38
18 · median 49
Started
2016
the only one that year
Phase 2
23 of 38
7 open now
Registered
5th of 38
by date

Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 31st largest by enrollment, is the only one that started in 2016, is one of 23 in phase 2, and was the 5th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing nivolumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer

Read the detailed description

This is a multicenter, single arm, safety lead-in, Phase 2 study, using Simon's 2 stage design evaluating the safety and efficacy of TAS-102 plus nivolumab in participants with Microsatellite-stable refractory metastatic colorectal cancer

Stage 1: Participants will be enrolled and after Cycle 1 treatment, they will be evaluated for the safety and tolerability of the combination therapy. Assuming a tolerated dose is confirmed additional participants evaluable for response will be enrolled and followed for a minimum of 6 months and there will be an interim analysis to assess the safety and efficacy to determine whether the second stage will open for enrollment.

Stage 2: Additional participant evaluable for response assessment will be enrolled and followed for a minimum of 6 months.

03

Conditions studied

  • Refractory Metastatic Colorectal Cancer

Keywords

  • Refractory
  • Metastatic
  • Colorectal cancer
  • TAS-102
  • Nivolumab
  • Microsatellite Stable
  • Programmed cell death protein1 (PD 1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written .
  2. Participants with confirmed proven or locally advanced colorectal adenocarcinoma who are microsatellite stable (MSS) (ie, not microsatellite instable [MSI]) based on either an analysis of tissue from a prior or based on tissue from a new biopsy.
  3. Participants with the presence of at least 1 lesion with as defined by 10 millimeters (mm) in the longest diameter for a soft tissue lesions or 15 mm in the short axis for a lymph node by (RECIST) and immune related response-criteria (irRC) for a response assessment.
  4. Participants has received at least 2 prior lines of standard chemotherapies for metastatic colorectal cancer (mCRC) and is to or failing those chemotherapies.
  5. Age greater than or equal to (>=) 18 years.
  6. performance status of 0 to 1
  7. of >=4 months.
  8. Has adequate organ function.
  9. Women of must have a negative pregnancy test (urine or serum) within 7 days before starting study drugs. Is able to take medications orally.
  10. Is able to take medications "orally".

Exclusion criteria

Exclusion Criteria:

  1. Has a serious illness or medical condition.
  2. Treatment with any of the following within the specified time frame before enrollment:

    1. Major surgery within the past 4 weeks (the surgical incision should be fully healed before study drug administration).
    2. Any anticancer therapy within the past 3 weeks before enrollment.
    3. Extended field radiation within the past 4 weeks or limited field radiation within the past 2 weeks before enrollment.
    4. Any drug/device received within the past 4 weeks or 5 times the half-life (whichever is shorter) before enrollment.
  3. Previous treatment with TAS-102.
  4. Prior treatment with anti-programmed cell death-1 (), anti-programmed cell death ligand (anti-PD-L1), anti programmed cell death ligand 2, anti-CD137, anti-OX-40, anti 0, anti cytotoxic T lymphocyte associated antigen-4 antibodies, or any other immune checkpoint inhibitors.
  5. Unresolved toxicity of >= version (CTCAE) version 4.03 grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum induced neurotoxicity).
  6. Prior events of immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune mediated nephritis and renal dysfunction, immune mediated rash, immune mediated encephalitis, and history of infusion reactions to nivolumab.
  7. Known or assumed to TAS-102 or nivolumab or any of its ingredients, including polysorbate 80-containing infusion.
  8. Previous severe hypersensitivity reaction to treatment with another mAb.
  9. Pregnant or lactating female.
  10. Inappropriate for entry into this study in the judgment of the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    TAS-102 + Nivolumab

    Participants received a dose of 35 milligrams per meter square (mg/m\^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).

    Drug: TAS-102 · Drug: nivolumab

Interventions

  • DrugTAS-102

    One Arm Only (of TAS 102 plus nivolumab)

    Also known as: Lonsurf®

  • One Arm Only (of TAS 102 plus nivolumab)

    Also known as: Opdivo®

06

What researchers measure

Primary outcomes

  1. Immune-Related Overall Response Rate (irORR)

    irORR was defined as the percentage of participants achieving a complete response (irCR) or partial response (irPR) based on irRC criteria. Per irRC criteria, Complete Response (irCR) was defined as the disappearance of all tumor lesions (measurable or not, and no new lesions)., Partial Response (irPR) was defined as a decrease in the sum of the products of the two largest perpendicular diameters (SPD) by 50 percent (%) or greater by a consecutive assessment at least 4 weeks after first documentation, Stable Disease (irSD) was defined as the failure to meet criteria for irCR or irPR in absence of progressive disease (irPD), irPD was defined as at least 25% increase in SPD relative to nadir.

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

Secondary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT: defined as occurrence of any of the following- Hematological toxicities: * Grade 4 neutropenia lasting greater than(\>)7 days * Grade 4 febrile neutropenia and fever greater than or equal to (\>=)38 degree celsius for over 1 hour * Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding or requiring transfusions Non-hematological toxicities: * Grade 3 or grade 4 non-hematologic toxicity (excluding alopecia, nausea, vomiting, diarrhea) * Grade 3 or grade 4 nausea/vomiting lasting \>48 hours and uncontrolled by aggressive anti-emetic therapy, including serotonin 5-HT3 receptor antagonists (e.g, ondansetron) * Grade 3 or grade 4 diarrhea lasting \> 48 hours and unresponsive to antidiarrheal medication Drug-related toxicities: * Any drug-related toxicity resulting in \> 2 weeks delay in initiation of Cycle 2 (i.e, cannot start Cycle 2 until Day 43 or later) * Any drug-related toxicity that prevents completion of 80% compliance for either drug in Cycle 1

    Time frame: Cycle 1 (each cycle is of 4 weeks)

  2. Recommended Phase 2 Dose (RP2D)

    RP2D of TAS-102 was evaluated based on the safety and tolerability of the combination therapy of TAS-102 and Nivolumab.

    Time frame: Cycle 1 (each cycle is of 4 weeks)

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs: AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

  4. Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities

    Hematological and chemistry laboratory tests abnormalities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

  5. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) version 1.1.CR was defined as the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (\<)10 millimeters (mm). PR was defined as at least a 30 % decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

  6. Progression-Free Survival (PFS) Based on Immune Related Response-Criteria (irRC)

    Immune-related progression free survival was defined as the time (in months) from the date of first dose of study treatment until the date of the investigator-assessed radiological disease progression (based on irRC) or death due to any cause. Participants who were alive with no disease progression at the moment of the analysis cut-off date was censored at the date of the last tumor assessment. Per irRC criteria disease progression defined as at least 25% increase in SPD relative to nadir. Analysis was performed using Kaplan-Meier estimates.

    Time frame: From the first dose of study treatment to disease progression or death (up to 53 weeks)

  7. Progression-Free Survival (PFS) Based on RECIST Criteria

    Progression free survival was defined as the time (in months) from the date of first dose of study treatment until the date of the investigator-assessed radiological disease progression (based on RECIST 1.1) or death due to any cause. Per RECIST criteria disease progression defined as least 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicated progression.

    Time frame: From the first dose of study treatment to disease progression or death (up to 53 weeks)

  8. Disease Control Rate (DCR) Based on irRC Criteria

    DCR was defined as the percentage of participants with objective evidence of radiologic complete response (CR), partial response (PR), or stable disease (SD) and was based on the overall best response from each participant as determined from investigator response assessments and following irRC criteria. Per irRC criteria, CR was defined as the disappearance of all tumor lesions (measurable or not, and no new lesions). PR was defined as a decrease in the sum of the products of the two largest perpendicular diameters by 50% or greater by a consecutive assessment at least 4 weeks after first documentation. SD was defined as the failure to meet criteria for irCR or irPR in absence of in absence of irPD.

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

  9. Disease Control Rate (DCR) Based on RECIST Criteria

    DCR was defined as the percentage of participants with objective evidence of radiologic CR, PR, or SD and was based on the overall best response from each participant as determined from investigator response assessments and following RECIST Criteria version 1.1. Per RECIST Criteria CR defined as disappearance of all target lesions. Reduction in any pathological lymph nodes in short axis to \<10 mm. PR defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameters during study.

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

  10. Overall Survival (OS)

    OS was defined as the time from the first dose of the study treatment to the death in the safety population. Participants alive at the time of the study discontinuation were censored. Analysis was performed using Kaplan-Meier estimates.

    Time frame: From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

07

Results

Posted Jul 26, 2021
Limitations and caveats
After interim analysis, per study design plan, the trial was stopped for futility before enrollment into Stage 2.

Participant flow

The study was conducted at 3 centers in United States.

Participant flow — Overall Study
MilestoneTAS-102 + Nivolumab
Started18
Completed0
Not completed18
Withdrew: Clinical progression6
Withdrew: Radiological progression12

Outcome measures

PrimaryImmune-Related Overall Response Rate (irORR)

irORR was defined as the percentage of participants achieving a complete response (irCR) or partial response (irPR) based on irRC criteria. Per irRC criteria, Complete Response (irCR) was defined as the disappearance of all tumor lesions (measurable or not, and no new lesions)., Partial Response (irPR) was defined as a decrease in the sum of the products of the two largest perpendicular diameters (SPD) by 50 percent (%) or greater by a consecutive assessment at least 4 weeks after first documentation, Stable Disease (irSD) was defined as the failure to meet criteria for irCR or irPR in absence of progressive disease (irPD), irPD was defined as at least 25% increase in SPD relative to nadir.

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)
Reported as:
Number · percentage of participants
Immune-Related Overall Response Rate (irORR)
percentage of participantsTAS-102 + Nivolumab
Immune-Related Overall Response Rate (irORR)0
SecondaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLT: defined as occurrence of any of the following- Hematological toxicities: * Grade 4 neutropenia lasting greater than(\>)7 days * Grade 4 febrile neutropenia and fever greater than or equal to (\>=)38 degree celsius for over 1 hour * Grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding or requiring transfusions Non-hematological toxicities: * Grade 3 or grade 4 non-hematologic toxicity (excluding alopecia, nausea, vomiting, diarrhea) * Grade 3 or grade 4 nausea/vomiting lasting \>48 hours and uncontrolled by aggressive anti-emetic therapy, including serotonin 5-HT3 receptor antagonists (e.g, ondansetron) * Grade 3 or grade 4 diarrhea lasting \> 48 hours and unresponsive to antidiarrheal medication Drug-related toxicities: * Any drug-related toxicity resulting in \> 2 weeks delay in initiation of Cycle 2 (i.e, cannot start Cycle 2 until Day 43 or later) * Any drug-related toxicity that prevents completion of 80% compliance for either drug in Cycle 1

Time frame:
Cycle 1 (each cycle is of 4 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsTAS-102 + Nivolumab
Number of Participants With Dose Limiting Toxicities (DLTs)0
SecondaryRecommended Phase 2 Dose (RP2D)

RP2D of TAS-102 was evaluated based on the safety and tolerability of the combination therapy of TAS-102 and Nivolumab.

Time frame:
Cycle 1 (each cycle is of 4 weeks)
Reported as:
Number · mg/m^2
Recommended Phase 2 Dose (RP2D)
mg/m^2TAS-102 + Nivolumab
Recommended Phase 2 Dose (RP2D)35
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs: AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
participantsTAS-102 + Nivolumab
Participants with TEAEs18
Participants with TESAEs6
SecondaryNumber of Participants With Grade 3 or Higher Laboratory Tests Abnormalities

Hematological and chemistry laboratory tests abnormalities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)
Reported as:
Number · participants
Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities
participantsTAS-102 + Nivolumab
Grade 4: Neutropenia (neutrophils low)3
Grade 4: Anemia (hemoglobin low)1
Grade 4: Leukopenia (leukocytes low)0
Grade 4: Lymphopenia (lymphocytes low)0
Grade 4: Thrombocytopenia (platelets low)0
Grade 4: Bilirubin High0
Grade 4: Glucose High0
Grade 4: Sodium Low0
Grade 3: Neutropenia (neutrophils low)3
Grade 3: Anemia (hemoglobin low)1
Grade 3: Leukopenia (leukocytes low)6
Grade 3: Lymphopenia (lymphocytes low)2
Grade 3: Thrombocytopenia (platelets low)1
Grade 3: Bilirubin High1
Grade 3: Glucose High1
Grade 3: Sodium Low1
SecondaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) version 1.1.CR was defined as the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (\<)10 millimeters (mm). PR was defined as at least a 30 % decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsTAS-102 + Nivolumab
Overall Response Rate (ORR)0
SecondaryProgression-Free Survival (PFS) Based on Immune Related Response-Criteria (irRC)

Immune-related progression free survival was defined as the time (in months) from the date of first dose of study treatment until the date of the investigator-assessed radiological disease progression (based on irRC) or death due to any cause. Participants who were alive with no disease progression at the moment of the analysis cut-off date was censored at the date of the last tumor assessment. Per irRC criteria disease progression defined as at least 25% increase in SPD relative to nadir. Analysis was performed using Kaplan-Meier estimates.

Time frame:
From the first dose of study treatment to disease progression or death (up to 53 weeks)
Reported as:
Median · months
Progression-Free Survival (PFS) Based on Immune Related Response-Criteria (irRC)
monthsTAS-102 + Nivolumab
Radiologic progression of disease only2.2 (1.8 to 6.0)
Radiologic + clinical progression of disease2.2 (1.8 to 3.7)
SecondaryProgression-Free Survival (PFS) Based on RECIST Criteria

Progression free survival was defined as the time (in months) from the date of first dose of study treatment until the date of the investigator-assessed radiological disease progression (based on RECIST 1.1) or death due to any cause. Per RECIST criteria disease progression defined as least 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study, including the baseline sum. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Definitive new lesion presence also indicated progression.

Time frame:
From the first dose of study treatment to disease progression or death (up to 53 weeks)
Reported as:
Median · months
Progression-Free Survival (PFS) Based on RECIST Criteria
monthsTAS-102 + Nivolumab
Radiologic progression of disease only2.8 (1.8 to 5.1)
Radiologic + clinical progression of disease2.5 (1.8 to 3.7)
SecondaryDisease Control Rate (DCR) Based on irRC Criteria

DCR was defined as the percentage of participants with objective evidence of radiologic complete response (CR), partial response (PR), or stable disease (SD) and was based on the overall best response from each participant as determined from investigator response assessments and following irRC criteria. Per irRC criteria, CR was defined as the disappearance of all tumor lesions (measurable or not, and no new lesions). PR was defined as a decrease in the sum of the products of the two largest perpendicular diameters by 50% or greater by a consecutive assessment at least 4 weeks after first documentation. SD was defined as the failure to meet criteria for irCR or irPR in absence of in absence of irPD.

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Based on irRC Criteria
percentage of participantsTAS-102 + Nivolumab
Disease Control Rate (DCR) Based on irRC Criteria44.4 (21.5 to 69.2)
SecondaryDisease Control Rate (DCR) Based on RECIST Criteria

DCR was defined as the percentage of participants with objective evidence of radiologic CR, PR, or SD and was based on the overall best response from each participant as determined from investigator response assessments and following RECIST Criteria version 1.1. Per RECIST Criteria CR defined as disappearance of all target lesions. Reduction in any pathological lymph nodes in short axis to \<10 mm. PR defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameters during study.

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Based on RECIST Criteria
percentage of participantsTAS-102 + Nivolumab
Disease Control Rate (DCR) Based on RECIST Criteria55.6 (30.8 to 78.5)
SecondaryOverall Survival (OS)

OS was defined as the time from the first dose of the study treatment to the death in the safety population. Participants alive at the time of the study discontinuation were censored. Analysis was performed using Kaplan-Meier estimates.

Time frame:
From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks)

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study treatment up to 30 days after the last dose of study treatment (up to 53 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAS-102 + Nivolumab0/18 (0%)6/18 (33.3%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventTAS-102 + Nivolumab
Abdominal painGastrointestinal disorders2/18
NauseaGastrointestinal disorders2/18
ColitisGastrointestinal disorders1/18
DiarrhoeaGastrointestinal disorders1/18
VomitingGastrointestinal disorders1/18
PyrexiaGeneral disorders1/18
CholangitisHepatobiliary disorders1/18
Urinary tract infectionInfections and infestations1/18
Confusional statePsychiatric disorders1/18
Obstructive uropathyRenal and urinary disorders1/18
Most frequent other events
Showing 10 of 62
Most frequent other events
EventTAS-102 + Nivolumab
NauseaGastrointestinal disorders12/18
DiarrhoeaGastrointestinal disorders11/18
VomitingGastrointestinal disorders6/18
FatigueGeneral disorders6/18
Neutrophil count decreasedInvestigations6/18
AnaemiaBlood and lymphatic system disorders5/18
Abdominal painGastrointestinal disorders5/18
ConstipationGastrointestinal disorders4/18
PruritusSkin and subcutaneous tissue disorders4/18
NeutropeniaBlood and lymphatic system disorders3/18

Baseline characteristics

Baseline population included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)TAS-102 + Nivolumab
Mean58.0 ± 7.32
Sex: Female, Male
Sex: Female, Male(Participants)TAS-102 + Nivolumab
Female9
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAS-102 + Nivolumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White12
More than one race0
Unknown or Not Reported2
08

Study locations

3 sites
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
09

References and documents

Publications

  • Patel MR, Falchook GS, Hamada K, Makris L, Bendell JC. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. Cancer Med. 2021 Feb;10(4):1183-1190. doi: 10.1002/cam4.3630. Epub 2021 Feb 5. PubMed 33544407 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study results using compiled efficacy and safety data will be published at congress or to a journal, without any identification of the patients.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Aug 2017, 12 months.

Results were first posted in Jul 2021, 3 years 11 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 12 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2016
First posted
Aug 9, 2016
StartActual
Aug 29, 2016
Primary completionActual
Aug 2017
CompletionActual
Sep 7, 2017
Results first posted
Jul 26, 2021
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02860546
Responsible party
Sponsor
First posted
Aug 9, 2016
Start date
Aug 29, 2016
Primary completion
Aug 2017
Completion
Sep 7, 2017
Results posted
Jul 26, 2021
Last update
Sep 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion